Delivery Characterization of SPL84 Inhaled Antisense Oligonucleotide Drug for 3849 + 10 kb C- > T Cystic Fibrosis Patients. 2023

Efrat Ozeri-Galai, and Lital Friedman, and Ofra Barchad-Avitzur, and Matthew R Markovetz, and William Boone, and Kaitlyn R Rouillard, and Chava D Stampfer, and Yifat S Oren, and David B Hill, and Batsheva Kerem, and Gili Hart
SpliSense, Biohouse Labs, Haddasah Ein Kerem, Jerusalem, Israel.

Recent advances in the therapeutic potential of RNA-related treatments, specifically for antisense oligonucleotide (ASO)-based drugs, have led to increased numbers of ASO regulatory approvals. In this study, we focus on SPL84, an inhaled ASO-based drug, developed for the treatment of the pulmonary disease cystic fibrosis (CF). Pulmonary drug delivery is challenging, due to a variety of biological, physical, chemical, and structural barriers, especially when targeting the cell nucleus. The distribution of SPL84 throughout the lungs, penetration into the epithelial cells and nucleus, and structural stability are critical parameters that will impact drug efficacy in a clinical setting. In this study, we demonstrate broad distribution, as well as cell and nucleus penetration of SPL84 in mouse and monkey lungs. In vivo and in vitro studies confirmed the stability of our inhaled drug in CF patient-derived mucus and in lung lysosomal extracts. The mobility of SPL84 through hyperconcentrated mucus was also demonstrated. Our results, supported by a promising preclinical pharmacological effect of full restoration of cystic fibrosis transmembrane conductance regulator channel activity, emphasize the high potential of SPL84 as an effective drug for the treatment of CF patients. In addition, successfully tackling the lung distribution of SPL84 offers immense opportunities for further development of SpliSense's inhaled ASO-based drugs for unmet needs in pulmonary diseases.

UI MeSH Term Description Entries
D008168 Lung Either of the pair of organs occupying the cavity of the thorax that effect the aeration of the blood. Lungs
D009841 Oligonucleotides Polymers made up of a few (2-20) nucleotides. In molecular genetics, they refer to a short sequence synthesized to match a region where a mutation is known to occur, and then used as a probe (OLIGONUCLEOTIDE PROBES). (Dorland, 28th ed) Oligonucleotide
D003550 Cystic Fibrosis An autosomal recessive genetic disease of the EXOCRINE GLANDS. It is caused by mutations in the gene encoding the CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR expressed in several organs including the LUNG, the PANCREAS, the BILIARY SYSTEM, and the SWEAT GLANDS. Cystic fibrosis is characterized by epithelial secretory dysfunction associated with ductal obstruction resulting in AIRWAY OBSTRUCTION; chronic RESPIRATORY INFECTIONS; PANCREATIC INSUFFICIENCY; maldigestion; salt depletion; and HEAT PROSTRATION. Mucoviscidosis,Cystic Fibrosis of Pancreas,Fibrocystic Disease of Pancreas,Pancreatic Cystic Fibrosis,Pulmonary Cystic Fibrosis,Cystic Fibrosis, Pancreatic,Cystic Fibrosis, Pulmonary,Fibrosis, Cystic,Pancreas Fibrocystic Disease,Pancreas Fibrocystic Diseases
D004364 Pharmaceutical Preparations Drugs intended for human or veterinary use, presented in their finished dosage form. Included here are materials used in the preparation and/or formulation of the finished dosage form. Drug,Drugs,Pharmaceutical,Pharmaceutical Preparation,Pharmaceutical Product,Pharmaceutic Preparations,Pharmaceutical Products,Pharmaceuticals,Preparations, Pharmaceutical,Preparation, Pharmaceutical,Preparations, Pharmaceutic,Product, Pharmaceutical,Products, Pharmaceutical
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D016376 Oligonucleotides, Antisense Short fragments of DNA or RNA that are used to alter the function of target RNAs or DNAs to which they hybridize. Anti-Sense Oligonucleotide,Antisense Oligonucleotide,Antisense Oligonucleotides,Anti-Sense Oligonucleotides,Anti Sense Oligonucleotide,Anti Sense Oligonucleotides,Oligonucleotide, Anti-Sense,Oligonucleotide, Antisense,Oligonucleotides, Anti-Sense
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus

Related Publications

Efrat Ozeri-Galai, and Lital Friedman, and Ofra Barchad-Avitzur, and Matthew R Markovetz, and William Boone, and Kaitlyn R Rouillard, and Chava D Stampfer, and Yifat S Oren, and David B Hill, and Batsheva Kerem, and Gili Hart
September 2021, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society,
Efrat Ozeri-Galai, and Lital Friedman, and Ofra Barchad-Avitzur, and Matthew R Markovetz, and William Boone, and Kaitlyn R Rouillard, and Chava D Stampfer, and Yifat S Oren, and David B Hill, and Batsheva Kerem, and Gili Hart
July 1995, Lancet (London, England),
Efrat Ozeri-Galai, and Lital Friedman, and Ofra Barchad-Avitzur, and Matthew R Markovetz, and William Boone, and Kaitlyn R Rouillard, and Chava D Stampfer, and Yifat S Oren, and David B Hill, and Batsheva Kerem, and Gili Hart
November 1998, Genomics,
Efrat Ozeri-Galai, and Lital Friedman, and Ofra Barchad-Avitzur, and Matthew R Markovetz, and William Boone, and Kaitlyn R Rouillard, and Chava D Stampfer, and Yifat S Oren, and David B Hill, and Batsheva Kerem, and Gili Hart
December 1996, Ear, nose, & throat journal,
Efrat Ozeri-Galai, and Lital Friedman, and Ofra Barchad-Avitzur, and Matthew R Markovetz, and William Boone, and Kaitlyn R Rouillard, and Chava D Stampfer, and Yifat S Oren, and David B Hill, and Batsheva Kerem, and Gili Hart
July 1993, Lancet (London, England),
Efrat Ozeri-Galai, and Lital Friedman, and Ofra Barchad-Avitzur, and Matthew R Markovetz, and William Boone, and Kaitlyn R Rouillard, and Chava D Stampfer, and Yifat S Oren, and David B Hill, and Batsheva Kerem, and Gili Hart
July 1998, Molecular genetics and metabolism,
Efrat Ozeri-Galai, and Lital Friedman, and Ofra Barchad-Avitzur, and Matthew R Markovetz, and William Boone, and Kaitlyn R Rouillard, and Chava D Stampfer, and Yifat S Oren, and David B Hill, and Batsheva Kerem, and Gili Hart
November 2017, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society,
Efrat Ozeri-Galai, and Lital Friedman, and Ofra Barchad-Avitzur, and Matthew R Markovetz, and William Boone, and Kaitlyn R Rouillard, and Chava D Stampfer, and Yifat S Oren, and David B Hill, and Batsheva Kerem, and Gili Hart
February 1996, American journal of respiratory and critical care medicine,
Efrat Ozeri-Galai, and Lital Friedman, and Ofra Barchad-Avitzur, and Matthew R Markovetz, and William Boone, and Kaitlyn R Rouillard, and Chava D Stampfer, and Yifat S Oren, and David B Hill, and Batsheva Kerem, and Gili Hart
January 2023, Molecules and cells,
Efrat Ozeri-Galai, and Lital Friedman, and Ofra Barchad-Avitzur, and Matthew R Markovetz, and William Boone, and Kaitlyn R Rouillard, and Chava D Stampfer, and Yifat S Oren, and David B Hill, and Batsheva Kerem, and Gili Hart
December 2004, Journal of controlled release : official journal of the Controlled Release Society,
Copied contents to your clipboard!